Cell reports. Medicine · 2026
Identification and characterization of bone marrow plasma cells producing IFN-γ-neutralizing autoantibodies in adult-onset immunodeficiency.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Han, Yang Qianqian, Zhao Tian, Yu Jinfang, Lei Yuqing, Yang Yuhan, Pan Siqi, Wang Xin, Hong Junxian, Wei Zimeng, Fan Xinyu, Li Jiaxiang, Wang Yaqi, Dong Haodi, Zhou Panpan, Zhang Qi, Shi Xuanling, Wang Jinglan, Wang Xinquan, Liu Peng, Fan Junping, Zhang Linqi
Аннотация
Adult-onset immunodeficiency (AOID) can be associated with anti-interferon (IFN)-γ autoantibodies (AIGAs). Rituximab (RTX) reduces circulating B cells but often fails to eliminate AIGAs, suggesting the presence of long-lived antibody-secreting cells (ASCs) in immune-privileged sites. Here, we identified 23 distinct IFN-γ-specific monoclonal antibodies (mAbs) from bone marrow (BM) ASCs of AOID patients using microwell array chip technology and single-cell RNA sequencing. Competitive assays demonstrated that neutralizing mAbs disrupt IFN-γ engagement with IFN-γR1 or IFN-γR2, impairing JAK-STAT1 signaling. Structural analysis of neutralizing mAb A01BM-03 revealed its binding to a quaternary epitope on dimeric IFN-γ, disrupting IFN-γR2 interaction. Notably, clonally expanded IFN-γ-specific ASCs were localized within a CD11c+ZEB2+ age-associated B cell (ABC)-like plasma cell cluster in one AOID patient, implicating its role in AOID pathogenesis. These findings provide direct evidence for IFN-γ-specific ASCs in the BM despite RTX treatment, supporting targeted ASC therapy to restore immune homeostasis in AOID.